• Bio-Path Holdings Inc., of Houston, said it started enrolling patients in the fourth dosage cohort for its Phase I trial of lead candidate BP-100.1.01 (liposomal Grb-1), which is being evaluated as a systemic treatment for blood cancers, including acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome.